Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug

Department of Materials Science and Engineering, 500 University Drive, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA
Biomaterials (Impact Factor: 8.31). 02/2008; DOI: 10.1016/j.biomaterials.2007.09.037

ABSTRACT Ceramide is a bioactive sphingolipid-derived second messenger that has been demonstrated to induce apoptosis and cell cycle arrest in various cancer cell culture systems. Although in vitro tumor cell culture models have illuminated the potential therapeutic utility of a cell-permeable analog of ceramide, C6, in vivo delivery is impeded by the extreme hydrophobicity and physical-chemical properties of this bioactive lipid. Previously, we have demonstrated that the incorporation of C6 into pegylated liposomal vesicles is an effective anti-cancer drug delivery strategy in vitro and in vivo. Here, we report the utilization of a novel multi-functional polymeric drug delivery system designed to therapeutically target C6 to solid tumor tissue. This delivery system is a hydrolytically degradable and temperature-sensitive linear-dendritic nanoparticle with a lower critical solution temperature (LCST) of 30 °C. C6 was effectively loaded into the nanoparticles, and released continuously for at least 1 month in vitro, measured by mass spectroscopy. The preferential uptake of fluorescein isothiocyanate-labeled linear-dendritic nanoparticles into human MDA-MB-231 breast adenocarcinoma cells at temperature above the LCST (37 °C) was confirmed by confocal microscopy and quantified by flow cytometry. The accumulation of NBD-C6 into MDA-MB-231 cells was highly enhanced by the thermoresponsive linear-dendritic nanoparticles, but not by non-thermoresponsive liposome and PEG-dendritic polymer, at temperature above the LCST (37 °C). The linear-dendritic nanoparticles alone were not toxic, but their complexes with C6 caused significant growth inhibition and apoptosis to MDA-MB-231 cells at 37 °C. The designed thermoresponsive and biodegradable linear-dendritic nanoparticles have great potential for thermally targeted and sustained release of C6 for the treatment of solid tumors with hyperthermia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Stimuli-responsive polymers are an important component for preparation of stimuli-responsive drug delivery systems with less side effects and improved efficacy for cancer treatment. There are endogenous stimuli and exogenous stimuli which can be explored. Here we review the developments in both endogenous stimuli- including redox-/pH-/enzyme-responsive polymers and exogenous stimuli- including thermo-/photo- and ultrasound-responsive polymers for delivery of anti-cancer drugs. Copyright © 2014 Elsevier B.V. All rights reserved.
    Materials Science and Engineering C 12/2014; 45:600-8. DOI:10.1016/j.msec.2014.05.050 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent developments in nanomedicine for the cancer therapy have enabled programmable delivery of therapeutics by exploiting the stimuli-responsive properties of nanocarriers. These therapeutic systems were designed with the relevant chemical and physical properties that respond to different triggers for enhanced anticancer efficacy, including the reduced development of drug-resistance, lower therapeutic dose, site-specific transport, and spatiotemporally controlled release. This minireview discusses the current advances in programmable nanocarriers for cancer therapy with particular emphasis on synergistic and sequential drug delivery systems.
    Nanoscale 01/2015; 7(8). DOI:10.1039/c4nr07677j · 6.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Different mechanisms in cancer cells become resistant to one or more chemotherapeutics is known as multidrug resistance (MDR) which hinders chemotherapy efficacy. Potential factors for MDR includes enhanced drug detoxification, decreased drug uptake, increased intracellular nucleophiles levels, enhanced repair of drug induced DNA damage, overexpression of drug transporter such as P-glycoprotein(P-gp), multidrug resistance-associated proteins (MRP1, MRP2), and breast cancer resistance protein (BCRP). Currently nanoassemblies such as polymeric/solid lipid/inorganic/metal nanoparticles, quantum dots, dendrimers, liposomes, micelles has emerged as an innovative, effective, and promising platforms for treatment of drug resistant cancer cells. Nanocarriers have potential to improve drug therapeutic index, ability for multifunctionality, divert ABC-transporter mediated drug efflux mechanism and selective targeting to tumor cells, cancer stem cells, tumor initiating cells, or cancer microenvironment. Selective nanocarrier targeting to tumor overcomes dose-limiting side effects, lack of selectivity, tissue toxicity, limited drug access to tumor tissues, high drug doses, and emergence of multiple drug resistance with conventional or combination chemotherapy. Current review highlights various nanodrug delivery systems to overcome mechanism of MDR by neutralizing, evading, or exploiting the drug efflux pumps and those independent of drug efflux pump mechanism by silencing Bcl-2 and HIF1α gene expressions by siRNA and miRNA, modulating ceramide levels and targeting NF-κB. "Theragnostics" combining a cytotoxic agent, targeting moiety, chemosensitizing agent, and diagnostic imaging aid are highlighted as effective and innovative systems for tumor localization and overcoming MDR. Physical approaches such as combination of drug with thermal/ultrasound/photodynamic therapies to overcome MDR are focused. The review focuses on newer drug delivery systems developed to overcome MDR in cancer cell.
    Frontiers in Pharmacology 07/2014; 5. DOI:10.3389/fphar.2014.00159